155 related articles for article (PubMed ID: 31920382)
1. Downregulation of CDH16 in Papillary Thyroid Cancer and Its Potential Molecular Mechanism Analysed by qRT-PCR, TCGA and in silico Analysis.
Li P; Wu Q; Sun Y; Pan X; Han Y; Ye B; Zhang Y; Dong J; Zheng Z
Cancer Manag Res; 2019; 11():10719-10729. PubMed ID: 31920382
[TBL] [Abstract][Full Text] [Related]
2. Loss of CDH16 expression is a strong independent predictor for lymph node metastasis in Middle Eastern papillary thyroid cancer.
Siraj AK; Parvathareddy SK; Al-Rasheed M; Annaiyappanaidu P; Siraj N; Lennartz M; Al-Sobhi SS; Al-Dayel F; Sauter G; Al-Kuraya KS
Sci Rep; 2023 Oct; 13(1):18559. PubMed ID: 37899424
[TBL] [Abstract][Full Text] [Related]
3. Cadherin-16 inhibits thyroid carcinoma cell proliferation and invasion.
Yang X; Li Y; Liu G; Zha W; Liu Y
Oncol Lett; 2022 May; 23(5):145. PubMed ID: 35350592
[TBL] [Abstract][Full Text] [Related]
4. New global analysis of the microRNA transcriptome of primary tumors and lymph node metastases of papillary thyroid cancer.
Saiselet M; Gacquer D; Spinette A; Craciun L; Decaussin-Petrucci M; Andry G; Detours V; Maenhaut C
BMC Genomics; 2015 Oct; 16():828. PubMed ID: 26487287
[TBL] [Abstract][Full Text] [Related]
5. A novel tumor suppressor gene
Zheng ZC; Wang QX; Zhang W; Zhang XH; Huang DP
Onco Targets Ther; 2018; 11():307-311. PubMed ID: 29391807
[TBL] [Abstract][Full Text] [Related]
6. Integrated microRNA, gene expression and transcription factors signature in papillary thyroid cancer with lymph node metastasis.
Ab Mutalib NS; Othman SN; Mohamad Yusof A; Abdullah Suhaimi SN; Muhammad R; Jamal R
PeerJ; 2016; 4():e2119. PubMed ID: 27350898
[TBL] [Abstract][Full Text] [Related]
7. Underexpression of INPPL1 is associated with aggressive clinicopathologic characteristics in papillary thyroid carcinoma.
Zhou YL; Zheng C; Chen YT; Chen XM
Onco Targets Ther; 2018; 11():7725-7731. PubMed ID: 30464521
[TBL] [Abstract][Full Text] [Related]
8. Low metallothionein 1M (MT1M) is associated with thyroid cancer cell lines progression.
Chen Y; Quan R; Bhandari A; Chen Z; Guan Y; Xiang J; You J; Teng L
Am J Transl Res; 2019; 11(3):1760-1770. PubMed ID: 30972199
[TBL] [Abstract][Full Text] [Related]
9. IGFBP3 as an indicator of lymph node metastasis and unfavorable prognosis for papillary thyroid carcinoma.
Huang Y; Chang A; Zhou W; Zhao H; Zhuo X
Clin Exp Med; 2020 Nov; 20(4):515-525. PubMed ID: 32596748
[TBL] [Abstract][Full Text] [Related]
10. DUSP4/MKP2 overexpression is associated with BRAF(V600E) mutation and aggressive behavior of papillary thyroid cancer.
Ma B; Shi R; Yang S; Zhou L; Qu N; Liao T; Wang Y; Wang Y; Ji Q
Onco Targets Ther; 2016; 9():2255-63. PubMed ID: 27143921
[TBL] [Abstract][Full Text] [Related]
11. Identification of biomarkers associated with cervical lymph node metastasis in papillary thyroid carcinoma: Evidence from an integrated bioinformatic analysis.
Zhang Z; Zhao S; Wang K; Shang M; Chen Z; Yang H; Chen Y; Chen B
Clin Hemorheol Microcirc; 2021; 78(2):117-126. PubMed ID: 33554894
[TBL] [Abstract][Full Text] [Related]
12. Expression profiling and bioinformatics analysis of serum exosomal circular RNAs in lymph node metastasis of papillary thyroid carcinoma.
Peng H; Zhu Z; Xing J; Xu Q; Man C; Wang S; Liu Y; Zhang Z
J Biomed Res; 2024 May; ():1-15. PubMed ID: 38812291
[TBL] [Abstract][Full Text] [Related]
13. ZCCHC12, a novel oncogene in papillary thyroid cancer.
Wang O; Zheng Z; Wang Q; Jin Y; Jin W; Wang Y; Chen E; Zhang X
J Cancer Res Clin Oncol; 2017 Sep; 143(9):1679-1686. PubMed ID: 28424903
[TBL] [Abstract][Full Text] [Related]
14. Long noncoding RNA ABHD11-AS1 functions as a competing endogenous RNA to regulate papillary thyroid cancer progression by miR-199a-5p/SLC1A5 axis.
Zhuang X; Tong H; Ding Y; Wu L; Cai J; Si Y; Zhang H; Shen M
Cell Death Dis; 2019 Aug; 10(8):620. PubMed ID: 31409775
[TBL] [Abstract][Full Text] [Related]
15. Downregulation of miR‑486‑5p in papillary thyroid carcinoma tissue: A study based on microarray and miRNA sequencing.
Wen DY; Pan DH; Lin P; Mo QY; Wei YP; Luo YH; Chen G; He Y; Chen JQ; Yang H
Mol Med Rep; 2018 Sep; 18(3):2631-2642. PubMed ID: 30015845
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of ITGA3 as a Biomarker of Progression and Recurrence in Papillary Thyroid Carcinoma.
Zhang G; Li B; Lin Y
Front Oncol; 2021; 11():614955. PubMed ID: 35174063
[TBL] [Abstract][Full Text] [Related]
17. Upregulated LAMB3 increases proliferation and metastasis in thyroid cancer.
Wang Y; Jin Y; Bhandari A; Yao Z; Yang F; Pan Y; Zheng Z; Lv S; Wang O
Onco Targets Ther; 2018; 11():37-46. PubMed ID: 29317832
[TBL] [Abstract][Full Text] [Related]
18. Integrated Characterization of MicroRNA and mRNA Transcriptome in Papillary Thyroid Carcinoma.
Mohamad Yusof A; Jamal R; Muhammad R; Abdullah Suhaimi SN; Mohamed Rose I; Saidin S; Ab Mutalib NS
Front Endocrinol (Lausanne); 2018; 9():158. PubMed ID: 29713312
[TBL] [Abstract][Full Text] [Related]
19. Thymosin beta 10 correlates with lymph node metastases of papillary thyroid carcinoma.
Zhang XJ; Su YR; Liu D; Xu DB; Zeng MS; Chen WK
J Surg Res; 2014 Dec; 192(2):487-93. PubMed ID: 24974154
[TBL] [Abstract][Full Text] [Related]
20. DNA methylation-mediated silencing of miR-204 is a potential prognostic marker for papillary thyroid carcinoma.
Xia F; Wang W; Jiang B; Chen Y; Li X
Cancer Manag Res; 2019; 11():1249-1262. PubMed ID: 30799952
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]